Kathy Wang, AstraZeneca AB, Sweden

Kathy Wang is a seasoned regulatory affairs professional with a robust track record in the medical device and drug-device combination product sectors. As the Regulatory Affairs Director for Devices and Digital Therapeutics at AstraZeneca, she plays a pivotal role in supporting the development and marketing of combined drug-device products. Kathy offers strategic regulatory guidance throughout the product lifecycle, from pre-clinical phases to market launch. Her international experience, gained from living and working in China, Australia, and Sweden, has fuelled her strong interest and expertise in global regulatory affairs.